Histone acetylation, a type of chromatin modification that allows increased gene transcription and can be pharmacologically promoted by histone deacetylase (HDAC) inhibitors (HDACis), has been consistently associated with promoting memory formation in the hippocampus. The basolateral nucleus of the amygdala (BLA) is a brain area crucially involved in enabling hormones and drugs to influence memory formation. Here, we show that BLA activity is required for memory enhancement by intrahippocampal administration of an HDACi. Two different HDACis, sodium butyrate (NaB) and trichostatin A (TSA), differentially enhanced the retention of memory for inhibitory avoidance (IA) when administered to the dorsal hippocampus after training. TSA showed a biphasic pattern of response during consolidation, in which infusions given immediately or 3 h after training produced memory enhancement, whereas no effect was observed when it was infused 1.5 or 6 h posttraining. Muscimol (MUS)-induced unilateral functional inactivation of the BLA prevented the enhancement of memory retention produced by posttraining infusion of TSA into the ipsilateral hippocampus. TSA did not affect IA extinction or reconsolidation. These results indicate that HDACis can increase IA memory retention when given into the hippocampus, and, most importantly, BLA activity is necessary for enabling HDACi-induced influences on memory formation.
Introduction
Gene expression associated with the formation of long-term memories is regulated by epigenetic processes that alter the chromatin state. Chromatin modifications allow for enduring alterations in the patterns of cell function without the need for changes in DNA sequence, thus constituting ideal candidate mechanisms mediating long-term alterations induced by learning (Gräff & Tsai, 2013) . Among the several types of epigenetic phenomena that occur in the brain and have been linked to memory formation, histone acetylation is the best studied (Barrett & Wood, 2008; Bridi & Abel, 2013; Gräff & Tsai, 2013; Levenson & Sweatt, 2005) . Histones constitute the major protein component of chromatin, and acetylation of their lysine residues by histone acetyltransferases (HATs) disrupts the interaction between histone and DNA, resulting in a ''relaxed'' chromatin structure that allows increased gene readout. An opposing role is played by histone deacetylases (HDACs), which, by removing acetyl groups, promote chromatin condensation and repress gene transcription (Haberland, Montgomery, & Olson, 2009; Kouzarides, 2007; Li, Carey, & Workman, 2007) .
HDAC types are divided into four groups: class I (HDAC1 -HDAC3 and HDAC8), class II (subdivided into class IIa, comprising HDAC4, HDAC5, HDAC7 and HDAC9, and class IIb, consisting of HDAC6 and HDAC10), class III (sirtuins), and class IV (HDAC11). All class I, II, and IV HDACs are expressed in neurons (Broide http Gräff & Tsai, 2013; Haberland et al., 2009 ). Formation of memory for contextual fear conditioning is accompanied by an increase in histone H3 acetylation in the CA1 area of the dorsal hippocampus (Levenson et al., 2004) . Overexpression of HDAC2 in mice impairs memory and long-term potentiation (LTP) in the hippocampus, whereas knocking it out enhances memory (Guan et al., 2009) , and HDAC3 deletion in the dorsal hippocampus enhances contextual fear . HDAC2 content is increased in the CA1 hippocampal area in mouse models of neurodegeneration as well as in the brains from patients with Alzheimer's disease, and an epigenetic blockade of gene transcription mediated by HDAC2 was associated with memory dysfunction in experimental neurodegeneration models (Gräff et al., 2012) .
The use of HDAC inhibitors (HDACis) is the most widely investigated pharmacological approach to produce memory enhancement through manipulating the epigenome. The HDACis most frequently used in memory experiments include sodium butyrate (NaB), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), and valproic acid (VPA). All these drugs inhibit preferentially class I HDACs, which are localized predominantly to the cell nucleus, and also act with lower activity on HDAC8. TSA and SAHA also inhibit HDAC6, the main cellular cytoplasmic deacetylase (Bhalla, 2005; Bolden, Peart, & Johnstone, 2006; Nott, Fass, Haggarty, & Tsai, 2013) . TSA facilitates LTP in the CA1 hippocampal area (Vecsey et al., 2007) as well as in amygdala slices (Monsey, Ota, Akingbade, Hong, & Schafe, 2011) . Systemic administration of NaB or VPA enhances fear memory formation and extinction (Bredy & Barad, 2008; Lattal, Barrett, & Wood, 2007; Levenson et al., 2004; Stafford, Raybuck, Ryabinin, & Lattal, 2012) . Intrahippocampal administration of TSA immediately after training enhances long-term contextual fear memory (Vecsey et al., 2007) , whereas NaB enhances fear extinction (Stafford et al., 2012) in mice. In addition to fear-motivated memory, studies using either systemic injections of NaB or posttraining intrahippocampal infusions of NaB, TSA, or the class I HDAC-selective inhibitor MS275 have found enhancement of long-term memory for specific types of object location or object recognition tasks in rats or mice (Haettig et al., 2011; Hawk, Florian, & Abel, 2011; Reolon et al., 2011; Roozendaal et al., 2010; Silva et al., 2012; Stefanko, Barrett, Ly, Reolon, & Wood, 2009) .
Extensive evidence indicates that normal activity of the basolateral nucleus of the amygdala (BLA) is required to mediate drug influences on memory consolidation for emotionally-arousing tasks (McGaugh, 2002; McGaugh, Cahill, & Roozendaal, 1996; McIntyre, McGaugh, & Williams, 2012; Roesler & McGaugh, 2010) . Selective lesions, functional inactivation, or pharmacological inhibition of the BLA block the effects of systemically administered drugs and hormones on memory (Quirarte, Roozendaal, & McGaugh, 1997; Roesler et al., 2004; . The BLA is also required for enabling the memory-enhancing effects of drugs infused directly into the hippocampus or related brain areas. Experiments using inhibitory avoidance (IA) showed that BLA lesions or intra-BLA administration of a noradrenergic antagonist can prevent the enhancement produced by posttraining intrahippocampal infusion of glucocorticoid receptor agonists on memory consolidation Roozendaal, Nguyen, Power, & McGaugh, 1999) , and excitotoxic lesions of the BLA block the memory-enhancing effect of administration of the cAMP analog 8-Br-cAMP into the entorhinal cortex (Roesler, Roozendaal, & McGaugh, 2002) . The functional interaction between the BLA and the hippocampus is restricted to the ipsilateral hemisphere. Thus, induction of hippocampal LTP is impaired by lesions of the ipsilateral BLA (Ikegaya, Saito, & Abe, 1994) , and inhibition of the noradrenergic system in the ipsilateral, but not the contralateral, BLA blocks the memory-enhancing effects of a glucocorticoid receptor agonist infused into the dorsal hippocampus (Roozendaal et al., 1999) . In addition, expression of the immediate-early gene Arc in the dorsal hippocampus is increased by administration of the b-adrenoreceptor agonist clenbuterol into the ipsilateral BLA.
Also, the BLA-hippocampal interaction seems to be specific to the dorsal part of the hippocampus, since intra-BLA clenbuterol does not affect Arc expression in the ventral hippocampus (McIntyre et al., 2005) . It is possible that the nucleus accumbens (NAc) is a critical site of convergence between the BLA and the dorsal hippocampus. The BLA projects directly to the NAc via the stria terminalis (ST), and the NAc in turn also receives direct projections from the hippocampus. Lesioning either the ST or the NAc blocks the memory enhancement induced by administration of a glucocorticoid receptor agonist into the BLA or the dorsal hippocampus (Roozendaal, de Quervain, Ferry, Setlow, & McGaugh, 2001) .
Although the effects of HDACis on memory have been increasingly investigated, little is known about the time course of HDACi enhancement of consolidation. In addition, previous studies have not verified whether the BLA influences the actions of HDACis given into other brain areas. In the present study, we describe the effects of administering NaB and TSA to the dorsal hippocampus on the consolidation of memory for IA, and examine the requirement of intact BLA activity in mediating the memory-enhancing effect of TSA.
Methods

Animals
Adult male Wistar rats (280-320 g at time of surgery) were obtained from the institutional breeding facility (CREAL, ICBS, UFRGS) and maintained at the university hospital experimental animal facility (UEA, CPE-HCPA). Animals were housed five per cage in plastic cages with sawdust bedding, and maintained on a 12 h light/dark cycle at a room temperature of 22 ± 1°C. The rats were allowed ad libitum access to standardized pellet food and water. All experiments took place during the light phase of the cycle, between 8 AM and 4 PM. All experimental procedures were performed in accordance with the Brazilian Guideline for the Care and Use of Animals in Research and Teaching (DBCA, published by CONCEA, MCTI; http://www.mct.gov.br/upd_blob/0226/226494. pdf) and were approved by the institutional animal care committee under protocol number 120068.
Surgery
Animals were implanted under anesthesia with ketamine (75 mg/kg) and xylasine (25 mg/kg) with either unilateral (left hemisphere) or bilateral 8.0-mm, 23-gauge guide cannulae aimed 1.0 mm above the CA1 area of the dorsal hippocampus, or unilateral (left hemisphere) 14-mm 23-gauge guide cannulae aimed 1.0 mm above the BLA, as described in previous reports (Jobim et al., 2012; Roesler et al., 2004; Roesler et al., 2006) . Coordinates (BLA, anteroposterior, À2.8 mm from bregma, mediolateral, ±4.8 mm from bregma, ventral, À7.5 mm from skull surface; DH anteroposterior, À4.3 mm from bregma; mediolateral, ±3.0 mm from bregma; ventral, À2.0 mm from skull surface) were obtained from the atlas of Paxinos and Watson (2007) . Animals were allowed to recover at least 7 days after surgery.
Intrahippocampal infusions and BLA inactivation
The general procedures for intrahippocampal infusions were as described in previous reports (Jobim et al., 2012; Roesler et al., 2006) . At the time of infusion, a 30-gauge infusion needle was fitted into the guide cannula. The tip of the infusion needle protruded 1.0 mm beyond the guide cannula and was aimed at either the BLA or the dorsal hippocampus. Drug or its respective control solution (saline or vehicle) was infused during a 30-s period. The infusion needle was left in place for an additional minute to allow diffusion of the drug away from the needle tip.
In experiments examining the effect of intrahippocampal administration of HDACis on memory consolidation, rats received a bilateral 1.0-ll infusion of NaB (Sigma-Aldrich, St. Louis, USA; 55, 100, or 250 mM) dissolved in saline (SAL, 0.9% NaCl), or TSA (Sigma-Aldrich; 22 mM) dissolved in 50% ethanol in saline (vehicle, VEH; Vecsey et al., 2007) , into the hippocampus immediately after training. Control animals received SAL in experiments using NaB and VEH in experiments using TSA. In the experiment examining the possible effects of TSA on reconsolidation or extinction, animals were given a bilateral 1.0-ll infusion of TSA (22 mM) or VEH immediately after the first test trial. In the experiment focusing on the possible BLA requirement for TSA-induced memory enhancement, unilateral functional inactivation of the left BLA was carried out as previously described (Roesler et al., 2004) by giving rats a unilateral 0.5-ll infusion of the c-aminobutyric acid type A (GABA A ) receptor agonist muscimol (MUS) (0.5 lg) (Sigma-Aldrich) dissolved in SAL into the left BLA 5 min before training. Control animals received an infusion of SAL. Immediately after training, the same animals were given a unilateral 1.0-ll infusion of VEH or TSA (22 mM) into the left dorsal hippocampus. In all experiments, drug dose ranges and appropriate vehicles were chosen on the basis of previous studies (Hawk et al., 2011; Lattal et al., 2007; Roozendaal et al., 2010; Stafford et al., 2012; Vecsey et al., 2007) . Drug solutions were freshly prepared before each experiment.
Inhibitory avoidance (IA)
Single-trial step-down IA is an established model of fear-motivated conditioning. In this task, animals learn to associate a location in the training apparatus (a grid floor) with an aversive stimulus (footshock). The general procedures for IA behavioral training and retention test were described in previous reports (Jobim et al., 2012; Roesler et al., 2004; Roesler et al., 2006) . The IA training apparatus was a 50 Â 25 Â 25-cm acrylic box (Albarsch, Porto Alegre, Brazil) whose floor consisted of parallel caliber stainless steel bars (1 mm diameter) spaced 1 cm apart. A 7-cm wide, 2.5-cm high platform was placed on the floor of the box against the left wall.
On training trials, rats were placed on the platform and their latency to step down on the grid with all four paws was measured with a digital chronometer. Immediately after stepping down on the grid, rats received a 0.4-mA, 3.0-s footshock and were removed from the apparatus immediately afterwards. Retention test trials took place at different intervals after training by placing the rats on the platform and recording their latencies to step down (see Section 3 for detailed procedures for each experiment). Depending on the experiment, rats were given up to six test trials. No footshock was presented during retention test trials. In the experiment examining possible drug effects on reconsolidation, rats that did not step down to the grid floor within 300 s during the 24-h test trial (''reactivation session'') were gently led by experimenter to the grid floor.
Step-down latencies on the retention test trial (maximum 300 s) were used as a measure of IA memory retention. In some of the experiments, at the end of series of test trials, rats were given a 0.3-mA reminder footshock (Tronel & Alberini, 2007) , followed by a retention test 24 h later.
Histology
Twenty-four to 72 h after behavioral testing, a 1.0-or 0.5-ll infusion of a 4% methylene blue solution was given into the dorsal hippocampus or BLA respectively. Rats were killed by decapitation 15 min later, and their brains were removed and stored in 10% formalin for at least 72 h. The brains were sectioned and examined for cannulae placements. The extension of the methylene blue dye was taken as indicative of diffusion of the drugs previously given to each rat, as previously described (Jobim et al., 2012; Roesler et al., 2004; Roesler et al., 2006) . Rats with incorrect cannula placements were excluded from the analysis.
Statistics
Data are shown as mean + S.E.M. retention test latencies to step-down (s). Comparisons of training and retention test stepdown latencies between control and drug-treated groups were performed using Kruskal-Wallis analysis of variance and MannWhitney U tests, two-tailed (Jobim et al., 2012; Roesler et al., 2004; Roesler et al., 2006) . In all comparisons, p < 0.05 was considered to indicate statistical significance.
Results
Enhancement of IA memory consolidation by posttraining administration of NaB into the dorsal hippocampus
The first experiment examined the effect of posttraining intrahippocampal administration of NaB on the retention of IA memory. Rats were given IA training followed by an infusion of SAL (N = 10) or NaB (55 mM, N = 10; 100 mM, N = 10; or 250 mM, N = 8) into the CA1 hippocampal area immediately after training. All rats were tested for retention 1 (Test 1), 2 (Test 2), 3 (Test 3), and 4 (Test 4) days after training. Based on the results showing that only the highest dose (250 mM) of NaB produced a significant effect, rats treated with this dose were given additional test trials at 11 (Test 5), and 21 (Test 6) days after training. Immediately after Test 6, rats were given a reminder footshock and tested again 1 day later.
Results are shown in Fig. 1 . There were significant differences between SAL-treated rats and rats given NaB at 250 mM in Test 1 (p < 0.01), Test 2 (p < 0.05), and Test 3 (p < 0.01), but not in the other behavioral trials. There were no significant differences between the SAL group and groups given NaB at 55 or 100 mM. There was a decline in retention levels across test trials, and both groups displayed similarly high latencies when tested after a reminder shock. The results indicate that NaB at the highest dose used produced an enhancement of IA memory retention that persisted for 3 days.
Time course of consolidation enhancement by intrahippocampal administration of TSA
Next, we aimed to compare the effects of posttraining NaB with those of TSA. Rats were trained as described above and given an infusion of VEH (N = 11) or TSA (22 mM, N = 13) into the hippocampus immediately after training. Retention tests were carried out 1 (Test 1), 2 (Test 2), 3 (Test 3), 4 (Test 4), 11 (Test 5), and 21 (Test 6) days after training. Immediately after Test 6, animals received a reminder footshock and were tested again 1 day later. There were significant differences between rats given VEH and TSA in Test 1 (p < 0.05), Test 2 (p < 0.01), Test 3 (p < 0.01), Test 4 (p < 0.05), and Test 5 (p < 0.05), but not in other behavioral trials. As in the previous experiment, one can observe a reduction in retention levels across test trials, and both groups displayed high latencies when tested after a reminder shock (Fig. 2A) . The results indicate that TSA administration resulted in significant enhancement of IA memory retention that lasted for 11 days.
For all subsequent experiments, TSA was chosen as the HDACi of use. When rats were trained and tested as above, but TSA was infused 1.5 h after training, no significant effect of TSA was observed ( Fig. 2B ; N = 7 rats per group). In contrast, an infusion given 3 h after training produced significantly enhanced retention in Tests 1, 2, and 3 (N = 9 rats per group; all ps < 0.05) (Fig. 2C) . Finally, TSA infusions given 6 h posttraining had no significant effect on memory tested up to 4 days after training ( Fig. 2D ; N = 11 rats per group). Due to the clear lack of drug effect, rats in this experiment were no further tested (see Figs. 3 and 4) 
Functional inactivation of the BLA prevents memory enhancement by intrahippocampal TSA administration
We then examined whether a functionally active BLA was required for intrahippocampal TSA to enhance memory. Rats were given a unilateral infusion of SAL or MUS into the left BLA before IA training, and a unilateral infusion of VEH or TSA into the hippocampus immediately after training as described in Section 2. The resulting experimental groups were SAL/VEH (N = 11); SAL/TSA (N = 15); MUS/VEH (N = 11); and MUS/TSA (N = 11). A retention test trial was carried out 24 h later. TSA administration induced a significant enhancement of retention (p < 0.001) in rats given intra-BLA SAL, whereas animals infused with MUS showed retention levels that did not differ from those in the control group, regardless of whether they received intrahippocampal VEH or TSA after training (Fig. 3) . These results indicate that MUS-induced BLA inhibition prevented the TSA enhancement of IA retention.
Post-retrieval administration of TSA into the hippocampus does not affect IA memory
In order to verify whether TSA would affect processes related to extinction or reconsolidation, rats were trained and tested for retention 1 day later (Test 1). Immediately after Test 1, an infusion of VEH (N = 14) or TSA (N = 11) was given into the hippocampus. Retention was tested again 1 day after the infusion (Test 2). There Fig. 1 . Administration of NaB into the hippocampus enhances long-term retention of IA memory. Rats were trained and given an infusion of SAL (N = 10) or NaB (55 mM, N = 10; 100 mM, N = 10; or 250 mM, N = 8) into the CA1 hippocampal area immediately after training. All rats were tested for retention 1 (Test 1), 2 (Test 2), 3 (Test 3), and 4 (Test 4) days after training. Animals treated with 250 mM NaB were given additional test trials at 11 (Test 5), and 21 (Test 6) days after training. Immediately after Test 6, rats were given a reminder footshock and tested again 1 day later. Data are mean + S.E.M. retention test latencies to step-down (s); Ã p < 0.05 and ÃÃ p < 0.01 compared to SALtreated rats. Fig. 2 . Biphasic enhancement of long-term memory for IA by intrahipocampal administration of TSA. (A) Rats were given IA training followed by an infusion of VEH (N = 11) or TSA (22 mM, N = 13) into the hippocampus. Retention was tested 1 (Test 1), 2 (Test 2), 3 (Test 3), 4 (Test 4), 11 (Test 5), and 21 (Test 6) days after training. Immediately after Test 6, animals received a reminder footshock and were tested again 1 day later. (B) Rats were trained and tested as described above, but infusion of VEH or TSA (22 mM, N = 7 rats per group) was given 1.5 h after training. (C) Rats were trained and tested as above, but infusion of VEH or TSA (22 mM, N = 9 rats per group) was given 3 h after training; (D) VEH or TSA (N = 11 rats per group) was infused 6 h after training, and retention was tested 1 (Test 1), 2 (Test 2), 3 (Test 3), and 4 (Test 4) days later. Data are mean + S.E.M. retention test latencies to step-down (s); were no significant differences between groups, indicating that TSA given after retrieval did not affect IA memory Fig. 4. 
Histology
All animals included in the final analysis (189 rats) had cannula placed in the intended sites. Fig. 5 shows schematic drawings of the diffusion of methylene blue, which indicates infusion placements and spread of drug infusions, within the dorsal hippocampus and BLA.
Discussion
The novel findings reported here can be summarized as follows:
(1) administration of the HDACis, NaB or TSA, into the dorsal hippocampus immediately after training enhanced retention of memory for IA; (2) The enhancement induced by TSA showed a biphasic temporal pattern during consolidation, in which memory retention was significantly enhanced by infusions given immediately after or 3 h training, but not when the drug was administered 1.5 or 6 h after training; (3) The enhancing effect of TSA infused unilaterally into the dorsal hippocampus was completely prevented by MUSinduced functional inactivation of the ipsilateral BLA; and (4) TSA given immediately after retrieval did not affect retention of IA memory.
Perhaps the most important finding of the present study was that functional inactivation of the BLA blocked the memoryenhancing effect of intrahippocampal TSA (Fig. 6) . As previously shown (Roesler et al., 2004) , unilateral inhibition of the left BLA induced by a high dose of MUS before training did not significantly affect IA memory retention per se, but could prevent the effect of another pharmacological intervention on memory consolidation. This is strongly consistent with the view that the BLA has a general and critical role as a brain area required to enable the influence of endogenous hormones, as well as of systemic or localized administration of drugs, on memory consolidation (McGaugh, 2002; McGaugh et al., 1996; McIntyre et al., 2012) . The present findings provide the first evidence indicating that this view should be extended to encompass epigenetic modulators, such as HDACIs, as agents that require BLA activity in order to be able to influence memory in other brain areas.
Previous studies have indicated that HDACis can enhance memory formation or extinction by increasing the acetylation of specific histone residues, such as histone 3 lysine residues 9 and 14 (H3K9/ 14), resulting in enhanced expression of genes related to synaptic plasticity and memory (Gräff & Tsai, 2013) . Facilitation of hippocampal memory and LTP by HDACis was shown to involve transcriptional activation mediated by cAMP-response elementbinding protein (CREB)-binding protein (CBP). Probably through this mechanism, TSA administration into the mouse hippocampus results in a selective and transient increase in the expression of genes related to synaptic plasticity and contextual fear, including Nr4a1, Nr4a2, and NGFI-B (nerve growth factor inducible-B) (Vecsey et al., 2007) . A recent seminal study showed that, in hippocampal extracts from mice given extinction training, systemic administration of the selective inhibitor of class I HDACs, CI-994, was associated with the differential expression of 475 genes between controls and CI-994-treated animals. Genes involved in hippocampal memory shown to be upregulated in response to CI-994 paired with extinction training included Arc, cFos, Npas4, and Igf2. These changes were accompanied by increased glucose utilization, facilitated LTP, enhanced dendritic branching, and an increase in the number of dendritic spines, in the hippocampi of mice given CI-994 (Gräff et al., 2014) .
The discussion on candidate mechanisms mediating the memory-enhancing effects of HDACis is further complicated because histones are not the only molecular targets of HDACis, which can also display activities independent of histone regulation of gene expression. For instance, transcription factors including E2F1, STAT1, STAT3, and NF-jB might be directly hyperacetylated by HDACis (Bolden et al., 2006; Glozak, Sengupta, Zhang, & Seto, 2005; Johnstone & Licht, 2003) , and in vitro experiments using brain tumor cells have indicated that TSA may influence protein kinase signaling through an acetylation-independent mechanism involving a disruption of HDAC-protein phosphatase 1 (PP1) complexes (Chen, Weng, Tseng, Lin, & Chen, 2005) . The possibility that HDACi induce effects directly on signaling pathways in the cytoplasm is particularly relevant for studies using TSA, which inhibits HDAC6, a predominatly cytoplasmic histone deacetylase, which likely has several mechanisms of action independent of alterations in gene expression mediated by increased histone acetylation (Chen et al., 2005; Glozak et al., 2005; Johnstone & Licht, 2003) .
In this regard, it is interesting to speculate on the mechanisms underlying our somewhat surprising finding that the time course . Administration of TSA into the hippocampus does not affect IA memory when given after retrieval. Rats were trained and given a retention test trial 1 day later (Test 1). Immediately after Test 1, VEH (N = 14) or TSA (22 mM; N = 11) was infused into the hippocampus. Retention was tested again 1 day after the infusion (Test 2). Data are mean + S.E.M. retention test latencies to step-down (s). There were no significant differences between groups.
of memory enhancement by posttraining administration of TSA showed a biphasic pattern, in which the effect was observed with infusions given shortly after training or 3 h later, but not at an intermediate time point. These findings support evidence from a previous study, which used the context-signal memory task in the Chasmagnathus granulatus crab to examine the time course of histone acetylation and HDACi effects during memory consolidation. The authors found that NaB injections resulted in memory enhancement when given immediately or 6 h posttraining, but not at 3 or 12 h after training, which is consistent with the two phases of PKA activity involved in consolidation in crabs (Federman, Fustiñana, & Romano, 2009) . In rats, similar patterns of two waves of drug effects in the hippocampus during consolidation of IA memory have previously been observed in experiments using a protein synthesis inhibitor (Quevedo et al., 1999) or drugs acting on the cAMP/protein kinase A (PKA)/CREB signaling pathway (Bevilaqua et al., 1997) . These effects are consistent with the well-established requirement of two waves of protein synthesis and PKA activity in the hippocampus for memory formation (Abel et al., 1997; Alberini, 2009; Kandel, 2012) . However, the mechanisms and time course of action of HDACis do not necessarily predict that their effects should display a similar two-phase pattern. Histone H3 acetylation in the mouse hippocampus was found to be significantly increased 4 h after intrahippocampal TSA administration (Vecsey et al., 2007) , making it unexpected that TSA infusions separated by short time intervals could produce markedly different effects, as was the case in our experiment. On the other hand, some effects of TSA seem to be more transient. Thus, the expression of Nr4a1 was significantly increased 2 h after TSA infusion and fear conditioning, but returned to normal levels by 4 h after conditioning (Vecsey et al., 2007) . It is possible that extra-epigenetic effects of TSA, such as interactions with proteins involved in cell signaling in the cytoplasm (Chen et al., 2005; Glozak et al., 2005) , rather than long-lasting alterations in gene expression, are predominantly involved in the TSA influences on consolidation. In addition, TSA might be more effective in modulating consolidation when its administration coincides with the waves of activation of protein synthesis and PKA activity in the hippocampus. Although detailing the mechanisms underlying the effects of TSA infusion given at different time points after learning falls out of the scope of the present study, future experiments should confirm and further explore the observed biphasic pattern for the effects of TSA infusions given during consolidation. Another aspect of our findings was related to the persistence of memory enhancement by HDACis, which is consistent with previous evidence indicating that increased acetylation induced by HDACis is a molecular feature of stronger and more persistent memories (Federman et al., 2009 ). Compared to controls, rats given NaB shortly after training, or TSA 3 h postraining, showed significantly enhanced retention for 3 days, whereas in rats given TSA immediately after training the effect persisted for 11 days. However, for both drugs, memory retention eventually returned back to basal levels in a relatively short period of time. It should be pointed out, however, that a proper evaluation of the effects of HDACis on memory persistence would require experiments using different animals tested at different time points, as well as doseresponse curves for all the drugs used. In step-down IA, repeated exposure to test trials in the absence of footshock exposure usually results in memory extinction, which can be influenced by drugs given upon retrieval (Vianna, Szapiro, McGaugh, Medina, & Izquierdo, 2001). Although in our experiments the drugs had an effect when given after training and not after retrieval, it cannot be ruled out that the decline in memory retention across multiple retention test trials was influenced by a differential processing of extinction in rats given posttraining HDACis compared to controls.
When TSA was infused after retrieval (i.e., post-first retention test) no significant alteration in IA memory retention tested 1 day later was observed. This is in contrast with previous reports showing that systemic or intrahippocampal administration of HDACis after retrieval can accelerate extinction of different types of conditioning (Bredy & Barad, 2008; Fujita et al., 2012; Gräff et al., 2014; Itzhak, Anderson, Kelley, & Petkov, 2012; Lattal et al., 2007; Malvaez, Sanchis-Segura, Vo, Lattal, & Wood, 2010; Malvaez et al., 2013; Raybuck, McCleery, Cunningham, Wood, & Lattal, 2013; Stafford et al., 2012; Wang, Zhang, Qing, Liu, & Yang, 2010) . Moreover, overexpression of HDAC1 in the mouse hippocampus (Bahari-Javan et al., 2012) or knockout of the HDAC2 gene in postmitotic forebrain neurons (Morris, Mahgoub, Na, Pranav, & Monteggia, 2013 ) predominantly affects extinction. Other studies have shown that HDACis administered systemically or into the amygdala around retrieval can lead to memory enhancement, an effect that has been interpreted as a facilitation of reconsolidation-like processes (Bredy & Barad, 2008; Maddox & Schafe, 2011) . Although pharmacological manipulation of the dorsal hippocampus after retrieval, using protocols similar to the one used in the present study, is capable of affecting both extinction and reconsolidation of IA memory (Jobim et al., 2012; Luft et al., 2006; Vianna et al., 2001) , it remains unclear which specific experimental parameters and boundaries determine the outcome of post-retrieval interventions in IA. Further experiments exploring different training, testing, and drug administration conditions are required to establish whether HDACis can influence retrieval-dependent memory modifications in this task.
In summary, here we show that the enhancement of IA memory consolidation produced by administration of an HDACi into the dorsal hippocampus depends on a functionally intact BLA. This is the first evidence indicating a critical role of the BLA in enabling memory enhancement by manipulation of epigenetic mechanisms in another brain area.
